跳转至内容
Merck
CN

P4153

Sigma-Aldrich

Prednisolone 21-hemisuccinate sodium salt

≥90%, powder

别名:

Δ1-Hydrocortisone 21-hemisuccinate, 1,4-Pregnadiene-11β,17,21-triol-3,20-dione 21-hemisuccinate, 11β,17α,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-hemisuccinate

登录查看公司和协议定价

选择尺寸

关于此项目

线性分子式:
C25H31O8Na
化学文摘社编号:
1715-33-9
分子量:
482.50
EC 号:
216-995-1
MDL编号:
MFCD00070045
UNSPSC代码:
51111800
PubChem化学物质编号:
24898507
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

synthetic

质量水平

200

无菌性

non-sterile

方案

≥90%

表单

powder

颜色

, White to Light Yellow to Light Beige

溶解性

hot water: 50 mg/mL, clear to very slightly hazy (Colorless to Light Yellow to Light Brown-Yellow)

运输

ambient

储存温度

−20°C

SMILES字符串

[Na].[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(=O)CCC(O)=O

InChI

1S/C25H32O8.Na.H/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;;/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30);;/t16-,17-,18-,22+,23-,24-,25-;;/m0../s1

InChI key

HLHQSPQPHMOTMP-FKIWUUNWSA-N

正在寻找类似产品? 访问 产品对比指南

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H360D

预防措施声明

P201 - P308 + P313

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCM7070
BCBW2082
BCBB6186V
BCBB6186
077K1581

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Shin-ichiro Kitajiri et al.
Archives of otolaryngology--head & neck surgery, 128(4), 365-367 (2002-04-03)
To assess the efficacy of corticosteroid therapy for sudden-onset sensorineural hearing loss at lower frequencies. Retrospective, nonrandomized, controlled study. The recovery rate, recovery/improvement rate, and period between the start of therapy and improvement of symptoms were studied in 2 groups:
Y Fujita et al.
Orthodontics & craniofacial research, 11(4), 187-195 (2008-10-28)
To analyse the effects of short-term treatment with etidronate on the glucocorticoid-induced retardation of bone growth and deterioration of bone structure in the prepubertal rat mandible. Fifty 5-week-old male rats were divided into five groups. Etidronate or vehicle treatment (5
Hong Yan et al.
Biological chemistry, 384(8), 1185-1194 (2003-09-17)
Previously we showed that glycation-induced inactivation and loss of antigenicity of enzymes occur simultaneously. Alpha-crystallin, a major structural protein of the mammalian lens, prevents the aggregation of other proteins and protects enzyme function against post-translational modification in vitro. However, it
Joanna Folwarczna et al.
Pharmacological reports : PR, 63(4), 1040-1049 (2011-10-18)
Glucocorticoid-induced osteoporosis is the most frequently occurring type of secondary osteoporosis. Antagonists of β-adrenergic receptors are now considered to be potential drugs under investigation for osteoporosis. The aim of the present study was to investigate the effects of propranolol, a
K Miyanishi et al.
Rheumatology (Oxford, England), 44(3), 332-336 (2004-12-16)
Osteonecrosis (ON) of the femoral head is a devastating complication occurring in patients receiving corticosteroid treatment. This study examined the effect of three corticosteroids on the development of ON in rabbits. Thirty-nine rabbits were injected once intramuscularly with either 25
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持